![\"\"](\"https:\/\/www.merckvaccines.com\/rotateq\/wp-content\/uploads\/sites\/168\/2025\/12\/Product-Information_FAQ_banner_1128px@2x.png?w=1488\")
<\/picture>Frequently asked questions <\/strong>about RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent)<\/mark><\/h1><\/p>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n\n<\/div>\n\n\n\n\nFind more information about RotaTeq<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the indication and usage for RotaTeq?<\/h4><\/summary>\n\n\n- RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.<\/li>
- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the dosing schedule for RotaTeq?<\/h4><\/summary>\n\n- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the Selected Safety Information for RotaTeq?<\/h4><\/summary>\n\nSelected Safety Information<\/strong><\/p>\n\n\n<\/div>\n\n\nRotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.<\/p>\n\n\n
<\/div>\n\n\nInfants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.<\/p>\n\n\n
<\/div>\n\n\nInfants with a history of intussusception should not receive RotaTeq.<\/p>\n\n\n
<\/div>\n\n\nNo safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.<\/p>\n\n\n
<\/div>\n\n\nIn a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.<\/p>\n\n\n
<\/div>\n\n\nNo safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.<\/p>\n\n\n
<\/div>\n\n\nVaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.<\/p>\n\n\n
<\/div>\n\n\nIn clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.<\/p>\n\n\n
<\/div>\n\n\nIn post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.<\/p>\n\n\n
<\/div>\n\n\nRotaTeq may not protect all vaccine recipients against rotavirus.<\/p>\n\n\n
Find more information about RotaTeq<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the indication and usage for RotaTeq?<\/h4><\/summary>\n\n\n- RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.<\/li>
- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the dosing schedule for RotaTeq?<\/h4><\/summary>\n\n- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the Selected Safety Information for RotaTeq?<\/h4><\/summary>\n\nSelected Safety Information<\/strong><\/p>\n\n\n<\/div>\n\n\nRotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.<\/p>\n\n\n
<\/div>\n\n\nInfants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.<\/p>\n\n\n
<\/div>\n\n\nInfants with a history of intussusception should not receive RotaTeq.<\/p>\n\n\n
<\/div>\n\n\nNo safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.<\/p>\n\n\n
<\/div>\n\n\nIn a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.<\/p>\n\n\n
<\/div>\n\n\nNo safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.<\/p>\n\n\n
<\/div>\n\n\nVaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.<\/p>\n\n\n
<\/div>\n\n\nIn clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.<\/p>\n\n\n
<\/div>\n\n\nIn post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.<\/p>\n\n\n
<\/div>\n\n\nRotaTeq may not protect all vaccine recipients against rotavirus.<\/p>\n\n\n
What is the indication and usage for RotaTeq?<\/h4><\/summary>\n\n\n- RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.<\/li>
- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the dosing schedule for RotaTeq?<\/h4><\/summary>\n\n- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the Selected Safety Information for RotaTeq?<\/h4><\/summary>\n\nSelected Safety Information<\/strong><\/p>\n\n\n<\/div>\n\n\nRotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.<\/p>\n\n\n
<\/div>\n\n\nInfants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.<\/p>\n\n\n
<\/div>\n\n\nInfants with a history of intussusception should not receive RotaTeq.<\/p>\n\n\n
<\/div>\n\n\nNo safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.<\/p>\n\n\n
<\/div>\n\n\nIn a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.<\/p>\n\n\n
<\/div>\n\n\nNo safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.<\/p>\n\n\n
<\/div>\n\n\nVaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.<\/p>\n\n\n
<\/div>\n\n\nIn clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.<\/p>\n\n\n
<\/div>\n\n\nIn post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.<\/p>\n\n\n
<\/div>\n\n\nRotaTeq may not protect all vaccine recipients against rotavirus.<\/p>\n\n\n
- RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.<\/li>
- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the dosing schedule for RotaTeq?<\/h4><\/summary>
\n\n- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>
What is the Selected Safety Information for RotaTeq?<\/h4><\/summary>
\n\nSelected Safety Information<\/strong><\/p>\n\n\n
<\/div>\n\n\nRotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.<\/p>\n\n\n
<\/div>\n\n\nInfants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.<\/p>\n\n\n
<\/div>\n\n\nInfants with a history of intussusception should not receive RotaTeq.<\/p>\n\n\n
<\/div>\n\n\nNo safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.<\/p>\n\n\n
<\/div>\n\n\nIn a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.<\/p>\n\n\n
<\/div>\n\n\nNo safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.<\/p>\n\n\n
<\/div>\n\n\nVaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.<\/p>\n\n\n
<\/div>\n\n\nIn clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.<\/p>\n\n\n
<\/div>\n\n\nIn post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.<\/p>\n\n\n
<\/div>\n\n\nRotaTeq may not protect all vaccine recipients against rotavirus.<\/p>\n\n\n
- The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.<\/li><\/ul><\/div>\n\n<\/div><\/details><\/div>\n\n\n\n